A phase II study of ERK inhibition by ulixertinib (BVD-523) in metastatic uveal melanoma.

Authors

null

Elizabeth Iannotti Buchbinder

Beth Israel Deaconess Medical Center, Boston, MA

Elizabeth Iannotti Buchbinder , Justine Vanessa Cohen , Rizwan Haq , F. Stephen Hodi , Donald P. Lawrence , Anita Giobbie-Hurder , Deb Knoerzer , Ryan J. Sullivan

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Melanoma/Skin Cancers

Track

Melanoma/Skin Cancers

Sub Track

Advanced/Metastatic Disease

Clinical Trial Registration Number

NCT03417739

Citation

J Clin Oncol 38: 2020 (suppl; abstr 10036)

DOI

10.1200/JCO.2020.38.15_suppl.10036

Abstract #

10036

Poster Bd #

385

Abstract Disclosures

Similar Posters

First Author: Rino S. Seedor

First Author: William Herrick

First Author: Kimberly Mayumi Komatsubara

Poster

2022 ASCO Annual Meeting

Outcomes of combined ipilimumab/nivolumab in metastatic uveal melanoma: A prevalence meta-analysis.

Outcomes of combined ipilimumab/nivolumab in metastatic uveal melanoma: A prevalence meta-analysis.

First Author: Ceren Durer